General Biotechnology

Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching

Russia’s biosimilar story is no longer a footnote—it’s a blueprint. And the most important part isn’t the headlines about “cost pressure” or “local manufacturing.” It’s the pipeline: a deliberate, patent-aware buildout that’s positioning Biocad to comp…

Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching Read Post »

General Biotechnology

Read the Drug Patent Clock Before the Market Does: A step-by-step technical guide to forecasting pharmaceutical drug patent expiry for IP teams, R&D strategists, and institutional investors

The drug patent clock is ticking—here’s how to read it before the market does.
Most IP teams don’t lose because they miss a filing. They lose because they misread time.
In pharma, “patent expiry” isn’t a single date on a calendar—it’s a moving target s…

Read the Drug Patent Clock Before the Market Does: A step-by-step technical guide to forecasting pharmaceutical drug patent expiry for IP teams, R&D strategists, and institutional investors Read Post »

Uncategorized

Drug Market Entry Intelligence: The Definitive Guide for Pharma Strategists, IP Teams, and Institutional Investors

Pharma’s next competitive edge won’t come from a new molecule—it will come from faster market entry intelligence.
For years, IP teams and pharma strategists have treated “market entry” like a downstream event: a filing here, a patent challenge there, a…

Drug Market Entry Intelligence: The Definitive Guide for Pharma Strategists, IP Teams, and Institutional Investors Read Post »

Biotechblog
Scroll to Top